Comparison between Placenta-derived Mesenchymal Stem/Stromal Cells and Bone-Marrow derived Mesenchymal Stem/Stromal cells on proliferation of neuroblastoma cell line SH-Y5Y

Children with high-risk neuroblastoma have survival rates of fewer than 50%, making it a prevalent yet heterogenous pediatric cancer. Due to their innate tumor homing, mesenchymal
stem/stromal cells (MSCs) may constitute a unique cellular delivery method. MSCs have, however, shown a range of effects on tumor formation. We examined the ability of bone marrow-derived MSCs (BM-MSCs) and placental MSCs (PMSCs) to promote or prevent the growth of neuroblastoma cells in culture. By gestational age and previously reported neuroprotective effects, PMSCs and BM-MSCs were compared. The proliferation of neuroblastoma cells is influenced differently by the MSC and neuroblastoma cell lines. BM-MSCs showed lesser proliferative effects than the majority of PMSCs, with the exception of when incubated with NB1643, suggesting that the impact of PMSCs on neuroblastoma cell development may differ by tumor.